Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...